Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Zhang, Li ^a   Chang, Wenqiang ^a   Sun, Bin ^a   Groh, Matthias ^b   Speicher, Andreas ^b   Lou, Hongxiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BIBENZYL DERIVATIVE; BISBIBENZYL DERIVATIVE; BS 34; FARNESOL; FLUCONAZOLE; GREEN FLUORESCENT PROTEIN; ISORICCARDIN C; ISORICCARDIN D; PLAGIOCHIN F; PLAGIOCHIN G; PLAGIOCHIN H; POLYMORPHATIN A; UNCLASSIFIED DRUG; FUNGAL PROTEIN; HYBRID PROTEIN;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; DPP3 GENE; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; FLUORESCENCE ANALYSIS; FUNGAL GENE; FUNGUS HYPHAE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT INTENSITY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MORPHOGENESIS; MOSS; NONHUMAN; QUORUM SENSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MYCELIUM; PHASE CONTRAST MICROSCOPY; PHYSIOLOGY;

ANTIFUNGAL AGENTS; BIBENZYLS; BIOFILMS; CANDIDA ALBICANS; FARNESOL; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GREEN FLUORESCENT PROTEINS; MICROSCOPY, PHASE-CONTRAST; MORPHOGENESIS; MYCELIUM; RECOMBINANT FUSION PROTEINS; UP-REGULATION;

EID: 83155176335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028953     Document Type: Article

References (36)

1. Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, (2004) Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 4: 369-376.
2. Balkis MM, Leidich SD, Mukherjee PK, Ghannoum MA, (2002) Mechanisms of fungal resistance: an overview. Drugs 62: 1025-1040.
3. Southern P, Horbul J, Maher D, Davis DA, (2008) C. albicans colonization of human mucosal surfaces. PLoS One 3: e2067.
4. Kobayashi SD, Cutler JE, (1998) Candida albicans hyphal formation and virulence: is there a clearly defined role? Trends Microbiol 6: 92-94.
5. Phan QT, Belanger PH, Filler SG, (2000) Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect Immun 68: 3485-3490.
6. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, López-Ribot JL, et al. (2009) Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci U S A 106: 599-604.
7. Kumamoto CA, Vinces MD, (2005) Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol 7: 1546-1554.
8. López-Ribot JL, (2005) Candida albicans biofilms: more than filamentation. Curr Biol 15: R453-R455.
9. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, et al. (2001) Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394.
10. Enjalbert B, Whiteway M, (2005) Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth. Eukaryot Cell 4: 1203-1210.
11. Ramage G, Saville SP, Wickes BL, López-Ribot JL, (2002) Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 68: 5459-5463.
12. Koo H, Hayacibara M, Schobel B, Cury J, Rosalen P, et al. (2003) Inhibition of Streptococcus mutans biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. J Antimicrob Chemother 52: 782-789.
13. Sato T, Watanabe T, Mikami T, Matsumoto T, (2004) Farnesol, a morphogenetic autoregulatory substance in the dimorphic fungus Candida albicans, inhibits hyphae growth through suppression of a mitogen-activated protein kinase cascade. Biol Pharm Bull 27: 751-752.
14. Nickerson KW, Atkin AL, Hornby JM, (2006) Quorum sensing in dimorphic fungi: farnesol and beyond. Appl Environ Microbiol 72: 3805-3813.
15. Navarathna DH, Hornby JM, Krishnan N, Parkhurst A, Duhamel GE, et al. (2007) Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 75: 1609-1618.
16. Dai Y, Sun LR, (2008) Advances in studies on bibenzyls naturally occurred in plant. Chin Tradit Herb Drugs 39: 1753-1756.
17. Guo XL, Leng P, Yang Y, Yu LG, Lou HX, (2008) Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump. J Appl Microbiol 104: 831-838.
18. Sun L, Sun S, Cheng A, Wu X, Zhang Y, et al. (2009) In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrobl Agents Chemother 53: 1586-1591.
19. Wilson RB, Davis D, Mitchell AP, (1999) Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol 181: 1868-1874.
20. Gillum A, Tsay E, Kirsch D, (1984) Isolation of the Candida albicans gene for orotidine-59-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198: 179-182.
21. Mason RE, Likar I, (1966) A new system of multiple-lead exercise electrocardiography. Am Heart J 71: 196-205.
22. Frade JP, Arthington-Skaggs BA, (2011) Effect of serum and surface characteristics on Candida albicans biofilm formation. Mycoses 54: e154-e162.
23. Chang WQ, Wu XZ, Cheng AX, Zhang L, Ji M, et al. (2011) Retigeric acid B exerts antifungal effect through enhanced reactive oxygen species and decreased cAMP. Biochim Biophys Acta 1810: 569-576.
24. Gerami-Nejad M, Berman J, Gale CA, (2001) Cassettes for PCR-mediated construction of green, yellow, and cyan fluorescent protein fusions in Candida albicans. Yeast 18: 859-864.
25. NCCLS (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Rashki Ghalehnoo Z, Rashki A, Najimi M, Dominguez A, (2010) The role of diclofenac sodium in the dimorphic transition in Candida albicans. Microb Pathog 48: 110-115.
27. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, et al. (2008) A simple and reproducible 96 well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 3: 1494-1500.
28. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL, (2001) Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45: 2475-2479.
29. Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, et al. (2001) Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 67: 2982-2992.
30. Cao YY, Cao YB, Xu Z, Ying K, Li Y, et al. (2005) cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrobl Agents Chemother 49: 584-589.
31. Xie CF, Lou HX, (2009) Secondary metabolites in bryophytes: an ecological aspect. Chem Biodivers 6: 303-312.
32. Davey ML, Currah RS, (2006) Interactions between mosses (Bryophyta) and fungi. Can J Bot 84: 1509-1519.
33. Wu XZ, Chang WQ, Cheng AX, Sun LM, Lou HX, (2010) Plagiochin E, an antifungal active macrocyclic bis (bibenzyl), induced apoptosis in Candida albicans through a metacaspase-dependent apoptotic pathway. Biochim Biophys Acta 1800: 439-447.
34. Cheng A, Sun L, Wu X, Lou H, (2009) The Inhibitory Effect of a Macrocyclic Bisbibenzyl Riccardin D on the Biofilms of Candida albicans. Biol Pharm Bull 32: 1417-1421.
35. Pagán-Mercado G, Rivera-Ruiz ME, Segarra-Román F, Rodríguez-Medina JR, (2009) antifungal research Strategies aiming for New targets. Puerto Rico Health Sciences Jo 28: 220-226.
36. Calderone RA, Fonzi WA, (2001) Virulence factors of Candida albicans. Trends Microbiol 9: 327-335.